INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number			10553361			
Filing Date			2005-10-14			
	First Named Inventor	Adnar	n Liam Gill			
Art Unit			1614			
	Examiner Name	Unkn	own			
	Attorney Docket Numb	er	2245 055			

Cite No	Patent Number	Kind Code ¹	Issue D	ate	of cited Document		Releva	nt Passag		
1	6414013		2002-07-	-02	Fancelli et al.	Fancelli et al.				
2	5571810		1996-11	-05	Matsuo et al.	Matsuo et al.				
3	4767758		1988-08-	-30	Breccia et al.					
h to a	dd additional U.S. Pater	t citatio	n informa	ation pl	ease click the	Add button.		Add		
		U.S.P	ATENT	APPLIC	CATION PUBL	LICATIONS		Remove		
Cite No	Publication Number			tion	of cited Document Relev			nt Passag		
1										
h to a	dd additional U.S. Publi	shed Ap	plication	citation	n information p	olease click the Ad	d button	Add		
			FOREIG	N PAT	TENT DOCUM	ENTS		Remove		
Cite No	Foreign Document Number ³				Publication Date		e or	vhere Rele Passages	evant or Relevant	Τs
1	03/004020	wo			2003-01-16					
	1 2 2 3 3 Cite No	No Patent Number 1 6414013 2 5571810 3 4767758 h to add additional U.S. Paten Cite No 1 to add additional U.S. Publication Number 1 Cite Foreign Document No Number?	No Patent Number Code1	No	No	No Patent Number Code Issue Date of cited Docu	No Patent Number Code ¹ Issue Date of cited Document 1 6414013 2002-07-02 Fancelli et al. 2 5571810 1996-11-05 Matsuo et al. 3 4767758 1996-08-030 Breccia et al. 1 to add additional U.S. Patent citation information please cick the Add button. U.S.PATENT APPLICATION PUBLICATIONS Cite Publication Number Code ¹ Publication 1 to add additional U.S. Published Application citation information please cick the Add button. See Publication Number Code ¹ Publication FOREIGN PATENT DOCUMENTS Cite Foreign Document Code ¹ i Code ¹ Date Name of Patentee or Applicant of cited Document of cited Document Code ¹ i Code ¹ Date Code ² i Code ² Publication Name of Patentee or Applicant of cited Document Code ² i Code ³ Date	Patent Number Code* Issue Date Name of Patentee or Application Relever of cited Document	Cide Patent Number Kind Issue Date Name of Patentes or Applicant Relevant Passag of cleded Document Relevant Passag Relevant	No Patent Number Code* Issue Date of cited Document Relevant Passages or Relev Figures Appear 1 6414013 2002-07-02 Farcelli et al. 2 5571810 1996-11-05 Matsuo et al. 3 4767759 1998-09-30 Precoa et al. 1 to add additional U.S. Patent clatation information please click the Add button. Add U.S. Patent Catation information please click the Add button. Semove Relevant Passages or Relev of cited Document Passages or Relev Figures Appear or Relev Figures Appear or Relev Relevant Passages or Relevant Rele

U.S. PATENTS

	Application Number		10553361		
	Filing Date		2005-10-14		
INFORMATION DISCLOSURE	First Named Inventor Adrian Li		Liam Gill		
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		1614		
(Not for Submission under or or it issue	Examiner Name	Unkno	own		
	Attorney Docket Numb	er	2245.055		

2	1 253 142	E₽	2002-10-30		
3	01/98301	wo	2001-12-27		
4	01/40223	wo	2001-06-07		
5	00/71535	wo	2000-11-30		
6	00/55152	wo	2000-09-21		
7	99/32477	wo	1999-07-01		
8	99/32463	wo	1999-07-01		
9	99/32111	wo	1999-07-01		
10	99/15164	wo	1999-04-01		
11	99/00357	wo	1999-01-07		
12	98/52558	wo	1998-11-26		

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10553361		
Filing Date		2005-10-14		
First Named Inventor	Adrias	n Liam Gill		
Art Unit		1614		
Examiner Name	Unkn	own		
		2245 055		

13	96/41795	wo		1996-12-27					
14	94/04525	wo		1994-03-03					
15	0 592 167	EP		1993-10-01					
16	93/14081	wo		1993-07-22					
17	10212271	JP		1998-08-11		abstract			
18	05230009	JP		1993-09-07		abstract			
h to a	d additional Foreign P								
							_		
Cite No	(book, magazine, jour	nal, serial, symp	osium,	catalog, etc), o	the article (when approp date, pages(s), volume-is	riate), title of the item isue number(s),	T5		
1	LANGE et al. "Synthesis of Highly Potent and Selective Hetaryl Ureas as Integrin avit3-Receptor Antagonists" J. Bioorg. Med. Chem. Lett. 12, 1379-1382 (2002).								
2	BINDER et al., "Theohene as Structural Element of Physiologically Active Compounds, X. Substituted 3- Alcoxy 4.5.6,7-tetrallystro-8H-theon(2,3-bjindoles* Arch. Pharm. (Wesheam), 314, 751-757 (1981)								
3 Abstract, 2000, 417122, KHMLAF of all "The synthesis of some head to head linked DNA minor groove binders" Tetrahedron, 56(29), 5225-5239 (2009).									
	14 15 16 17 18 10 to ac Cite No	14 94/04525 15 0 592 167 16 93/14081 17 10212271 18 05230009 10 add additional Foreign P Citle (hook, magazine, jum publisher, city andior. 1 LANCS et al., "Shates Bioorg Med. Chem. Left 2 BINDER et al., "Thoophe Alkoxy-4.5.6,7 iderahyde	14 94/04525 WO 15 0 592 167 EP 16 93/14081 WO 17 10212271 JP 18 05230008 JP 10 add additional Foreign Patent Document NON-PATE Citle (Dick magazine, journal, serial, symp publisher, and John School, source out on the surface for patent Dock magazine, journal, serial, symp publisher, and John School, source out by where p 1 LANGE et al., "Synthesis of Highly Potent Bioorg Med. Chem. Left. 12, 1379-1382 G 2 BINDER et al., "Thickphene as Structural E Alcony.4.5.6.7, fetraltydro.81+9 tencil.2.3-bit Abstract. 2000. 47/1722, KHMLAF et al."	14 94/04525 WO 15 0 592 167 EP 16 93/14081 WO 17 10212271 JP 18 05230006 JP 10 104 dd ddditional Foreign Patient Document citation NON-PATENT UTIL Citle Nobok magazine, journal, serial, symposium, publisher, dily andior country where publisher in the patient of the the	14 94/04525 WO	14 94/04525 WO	14 94/04525 WO		

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

plication Number		10553361			
ing Date		2005-10-14			
st Named Inventor Adrian		Liam Gill			
t Unit		1614			
aminer Name	Unkn	own			
torney Docket Number		2245 055			

Date Considered

EXAMINER SIGNATURE										
If you wish to add additional non-patent literature document citation information please click the Add button Add										
	7	REDMAN et al., "p38 Kinase inhibitors for the Treatment of Arthritis and Osteoporosis: Therryl, Furyl, and Pyrrolyl Ureas*, Boorg. Med. Chem., Lett., 11, 9-12 (2001).								
	6	Abstract 79:53221, GEWALD et al., "2-Aminotheno[2.3-d]thazoles and 3-amnotheno[2.3-d]sothiazoles' J. Prak. Chem. 315(3), 539-548 (1973).								
	5	Abstract 100:34354, GUDRINIECE et at, "Helerocyclic compounds from dikatones XXIX 2-Amino-3-cyano-5- ethoxycarbonyi-4-methythophene and some of its properties" Kmijas Serja 5, 614-617 (1993).								
	4	Abstract, 115 232166, GEWALD et al., "The reaction of 2-aminothophene-3-carbonfriles with heterocumulenes", J. Prakt. Chem. 333(2), 229-236 (1991).								

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See ford Codes of UBFTO Potent Douments at year, UBFTO GOV, or NEPE 9010. I. Enter office that issued the document, by the ho-faster code (WPD Standard STS), 3 February see parts documents, the modision for layer of the religion february seems from the companies of the seems from the ordinary of the seems from the ordinary of the seems of the seems from the ordinary of the seems from the ordinary of the seems of the ordinary of the seems of the ordinary of the seems of the ordinary of the

Examiner Signature

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10553361			
Filing Date		2005-10-14			
First Named Inventor	Adrias	Liam Gill			
Art Unit		1614			
Examiner Name	Unkno	own			
Attorney Docket Numb	ec	2245 055			

CERTIFICATION STATEMENT

Diagra can	37	CFR .	1 97	and	1 02	to make	the	appropriate	coloction/	e)·

That each item of information contained in the information disclosure statement was first cited in any communication
from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office is a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1/56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1/97(c).

See attached certification statement.	

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

▼ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Torm or the signature.				
	Signature	/Philip E. Hansen/	Date (YYYY-MM-DD)	2006-10-31
	Name/Print	Philip E. Hansen	Registration Number	32 700

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary Cfiling. U.S. Operatment of Commence, P. 0. Box 1450, Alexandria, V.S. 2313-1450. D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record perfains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.